Kailera Therapeutics (KLRA) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$1.09

Estimate

-$0.76

Surprise

-43.4%

Score today

4.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Kailera Therapeutics (KLRA) reported a wider loss than forecast — diluted EPS of -$1.09 against the -$0.76 estimate (a 43.4% shortfall).

• Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate — benzinga, 2026-08-12

TrendMatrix currently rates KLRA Sell at 4.9/10; no pre/post engine snapshot brackets this report.

0 of the last 2 quarters beat the estimate; this quarter's -43.4% surprise compares with a -307.2% four-quarter average. Next scheduled report: 2026-10-29.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$12.75

Price target

$18.40

Stop

$12.10

Upside to target

+44.3%

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.74B

P/E (fwd)

-3.1

52-week range

$13.32–$28.23

Off 52-week high

54.8%

RSI (14)

20

Volume vs avg

1.35×

Score today

4.9/10